+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Biological Therapy Market - Global Forecast 2026-2032- Product Image
Cancer Biological Therapy Market - Global Forecast 2026-2032- Product Image
Sale

Cancer Biological Therapy Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011650
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Biological Therapy Market is projected to reach USD 225.03 Billion in 2026. It is expected to continue growing at a CAGR of 7.45%, reaching USD 347.87 Billion by 2032.

Cancer biological therapy is reshaping oncology by using the immune system, engineered cells, antibodies, vaccines, cytokines, and targeted biologics to identify and destroy malignant cells with greater specificity than conventional chemotherapy. Demand is supported by the global cancer burden, with the International Agency for Research on Cancer reporting about 20 million new cancer cases and 9.7 million cancer deaths in 2022, and projecting new cancer cases to rise to more than 35 million by 2050.

Market momentum is strongest in immune checkpoint inhibitors, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, CAR-T cell therapies, cancer vaccines, oncolytic viruses, and next-generation cell and gene therapies. Adoption is increasingly tied to biomarker testing, companion diagnostics, real-world evidence, and reimbursement models that link clinical value to outcomes, including overall survival, durable response, safety, and patient quality of life.

Transformative Shifts in Cancer Biological Therapy

The cancer biological therapy landscape is moving from broad immunotherapy adoption toward precision immune modulation. PD-1, PD-L1, and CTLA-4 checkpoint inhibitors have established immuno-oncology as a standard component of care across melanoma, lung cancer, renal cell carcinoma, bladder cancer, head and neck cancer, gastrointestinal cancers, and several hematologic malignancies, while combination regimens are expanding treatment options.

At the same time, cell therapies, bispecific antibodies, antibody-drug conjugates, and tumor-agnostic biologic strategies are shifting competition toward differentiated mechanisms, manufacturing reliability, and patient selection. The market is also being transformed by subcutaneous formulations, outpatient administration, decentralized trials, biosimilar competition for mature biologics, and health technology assessment requirements that demand measurable survival, response, safety, and quality-of-life benefits.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across cancer biological therapy discovery, clinical development, manufacturing, and commercialization. AI-enabled platforms are used to identify tumor antigens, prioritize immune targets, model protein interactions, screen antibody candidates, optimize cell therapy constructs, and analyze multi-omics datasets that can improve biomarker-driven patient stratification.

In clinical practice and development, AI supports radiology, digital pathology, trial matching, toxicity monitoring, pharmacovigilance, and real-world evidence generation. Its impact is strongest when paired with validated datasets, transparent governance, and regulatory-grade documentation. For industry leaders, AI is not a standalone replacement for biological validation; it is an accelerator that can reduce cycle time, improve trial design, strengthen manufacturing analytics, and support safety monitoring for complex oncology biologics.

Regional Insights Across Cancer Biological Therapy

North America remains a leading region for cancer biological therapy innovation, supported by FDA oncology approvals, high biomarker testing adoption, major academic cancer centers, and strong venture and biopharmaceutical investment. The United States anchors clinical trial activity and early adoption of immuno-oncology, cell therapy, bispecific antibodies, and antibody-drug conjugates, while Canada supports evidence-based access through provincial reimbursement systems, oncology networks, and national cancer control initiatives.

Europe is shaped by EMA regulation, national health technology assessment, pharmacovigilance standards, and strong research infrastructure across the European Union, the United Kingdom, Germany, France, Italy, and Spain. Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, and Australia increase domestic biologics capacity, oncology trials, biosimilar production, genomic testing, and cell therapy research. Latin America, led by Brazil and Mexico, is improving oncology access through public and private care channels but still faces reimbursement, diagnostic, and infrastructure gaps. The Middle East, especially GCC markets, is investing in specialty care, oncology centers, genomic medicine, and precision oncology hubs, while Africa remains focused on earlier diagnosis, pathology capacity, trained workforce, cold-chain infrastructure, and equitable biologics availability.

Group Insights Shaping Market Access

The European Union supports cancer biological therapy through centralized regulatory pathways, cross-border research programs, pharmacovigilance standards, rare disease and advanced therapy frameworks, and increasing use of joint clinical assessment. G7 markets remain central to oncology R&D, premium biologics launches, intellectual property creation, clinical guideline development, and payer frameworks that evaluate overall survival, progression-free survival, safety, patient-reported outcomes, and comparative value.

BRICS countries are becoming more influential through larger patient populations, expanding domestic manufacturing, biosimilar development, public health investment, and growing clinical trial participation, particularly in China, India, and Brazil. ASEAN markets are strengthening regulatory cooperation, hospital oncology capacity, and access to biosimilars, though availability varies widely by income level, specialist workforce, and reimbursement maturity. GCC countries are using national cancer strategies, procurement scale, digital health investment, and tertiary care expansion to accelerate adoption. NATO members are relevant to supply-chain resilience, cybersecurity, emergency preparedness, and continuity planning for high-value biologics, advanced therapies, and cold-chain medicines.

Country Insights for Cancer Biological Therapy

The United States leads cancer biological therapy commercialization through FDA expedited pathways, extensive oncology networks, biomarker testing infrastructure, and strong uptake of immuno-oncology, CAR-T cell therapy, bispecific antibodies, and antibody-drug conjugates. Canada emphasizes evidence-based reimbursement and coordinated cancer care, while Mexico and Brazil represent major Latin American opportunities where private-sector adoption is often faster than public access. The United Kingdom combines MHRA oversight, NICE assessment, the Cancer Drugs Fund, and genomic medicine initiatives, while Germany and France remain major European launch markets with advanced oncology infrastructure, early access mechanisms, and strong clinical research activity.

Italy and Spain show strong clinical adoption within national health systems, supported by specialist oncology centers and participation in multinational trials, while Russia has focused on local biologics production amid changing trade and regulatory conditions. China is rapidly advancing domestic PD-1 inhibitors, antibody platforms, biosimilars, and cell therapy pipelines. India is expanding biosimilars, clinical research capacity, and cost-sensitive oncology access. Japan maintains high regulatory quality, universal healthcare coverage, and early innovation adoption, South Korea is a strong biologics manufacturing and clinical research hub, and Australia supports oncology trials through high-quality care networks, precision medicine programs, and regulatory alignment with global standards.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led development, companion diagnostic integration, and adaptive trial designs that identify responders earlier and improve evidence quality. Competitive advantage will increasingly depend on proving differentiated survival benefit, manageable toxicity, durable response, feasible administration, and patient-relevant outcomes in real-world oncology settings.

Organizations should invest in scalable biologics manufacturing, cold-chain reliability, cell therapy logistics, release testing, and quality systems that meet global regulatory expectations. Market access teams should build evidence packages for payers early, including comparative effectiveness, health economics, budget impact logic without unsupported forecasts, and real-world outcomes. Partnerships with academic cancer centers, diagnostics developers, AI specialists, contract manufacturers, and regional production networks can accelerate development while improving affordability, geographic reach, and continuity of supply.

Research Methodology

This executive summary is based on secondary research and market intelligence synthesis from authoritative oncology, regulatory, clinical, and public health sources. Inputs include global cancer burden data from IARC and WHO, regulatory information from agencies such as FDA and EMA, clinical development trends from oncology trial registries, and peer-reviewed evidence on immunotherapy, cell therapy, antibodies, antibody-drug conjugates, vaccines, and biomarker-guided treatment.

The methodology emphasizes triangulation across disease burden, approval activity, therapeutic class evolution, regional access dynamics, reimbursement patterns, manufacturing capacity, diagnostic readiness, and technology adoption. Insights were reviewed for consistency, commercial relevance, and applicability to the cancer biological therapy market, with preference given to verified public data, established clinical evidence, regulatory publications, and recognized oncology practice guidelines.

Conclusion: Future of Cancer Biological Therapy

Cancer biological therapy is entering a more selective, data-driven, and outcomes-focused phase. Immuno-oncology has become a foundation of modern cancer care, while bispecific antibodies, cell therapies, antibody-drug conjugates, cancer vaccines, oncolytic viruses, and engineered immune platforms are broadening the treatment landscape.

Future progress will depend on better biomarkers, scalable manufacturing, AI-enabled development, payer-ready evidence, and equitable access across mature and emerging markets. Organizations that combine scientific differentiation with operational execution, regulatory discipline, supply-chain resilience, and patient-centered value will be best positioned to lead the next wave of oncology biologics innovation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cancer Biological Therapy Market, by Therapy Type
7.1. Introduction
7.2. Cancer Vaccines
7.3. CAR T-Cell Therapy
7.4. Cytokine Therapy
7.5. Gene Therapy
7.6. Monoclonal Antibodies
7.6.1. Chimeric
7.6.2. Human
7.6.3. Murine
7.7. Oncolytic Viral Therapy
8. Cancer Biological Therapy Market, by Administration Route
8.1. Introduction
8.2. Intramuscular
8.3. Intravenous
8.4. Oral
8.5. Subcutaneous
9. Cancer Biological Therapy Market, by Application
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Hematologic Malignancies
9.5. Melanoma
9.6. Non-Small Cell Lung Cancer
9.7. Prostate Cancer
10. Cancer Biological Therapy Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Home Healthcare
10.4. Hospitals
10.5. Research Laboratories
10.6. Specialty Clinics
11. Cancer Biological Therapy Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Cancer Biological Therapy Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Cancer Biological Therapy Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Cancer Biological Therapy Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Amgen Inc.
16.3. Astellas Pharma Inc.
16.4. AstraZeneca PLC
16.5. Autolus Therapeutics plc
16.6. Bayer AG
16.7. BeiGene, Ltd.
16.8. BioNTech SE
16.9. Bristol-Myers Squibb Company
16.10. C4 Therapeutics, Inc.
16.11. CRISPR Therapeutics AG
16.12. Daiichi Sankyo Company, Limited
16.13. Eli Lilly and Company
16.14. F. Hoffmann-La Roche Ltd
16.15. Gilead Sciences, Inc.
16.16. GSK plc
16.17. Incyte Corporation
16.18. Iovance Biotherapeutics, Inc.
16.19. Jazz Pharmaceuticals plc
16.20. Johnson & Johnson
16.21. Legend Biotech Corporation
16.22. MacroGenics, Inc.
16.23. Merck & Co., Inc.
16.24. Moderna, Inc.
16.25. Novartis AG
16.26. Pfizer Inc.
16.27. Regeneron Pharmaceuticals, Inc.
16.28. Seagen Inc.
16.29. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL CANCER BIOLOGICAL THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANCER BIOLOGICAL THERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CHIMERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CHIMERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CHIMERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HUMAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HUMAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL HUMAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MURINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MURINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MURINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ONCOLYTIC VIRAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ONCOLYTIC VIRAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ONCOLYTIC VIRAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 94. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 96. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 97. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 98. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 99. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 100. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 117. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 118. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 119. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 120. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 121. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 132. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 133. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 134. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 135. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 137. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 139. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 140. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 141. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 142. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 143. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 144. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 146. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 147. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 148. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 149. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 153. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 160. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 161. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 162. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 163. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 164. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 165. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 167. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 168. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 169. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 170. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 173. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 174. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 175. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 176. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 177. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 178. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 179. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 180. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 181. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 182. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 183. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 184. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 185. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 186. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 187. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 188. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 189. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 190. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 191. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 192. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 194. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 195. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 196. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 197. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 198. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 199. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 201. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 202. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 203. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 204. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 205. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 206. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 208. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 209. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 210. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 211. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 212. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 213. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 215. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 216. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 217. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 218. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 219. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 220. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 221. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 222. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 224. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 225. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 226. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 227. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 229. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 230. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 231. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 232. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 233. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 234. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 236. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 238. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 239. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 240. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 241. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 243. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 245. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 246. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 247. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 248. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 250. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 251. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 252. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 253. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 254. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 255. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 256. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 257. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 259. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 260. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 261. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 262. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 264. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 266. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 267. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 268. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 269. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 270. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 271. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 273. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 274. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 275. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 276. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 278. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
TABLE 279. GLOBAL CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Autolus Therapeutics plc
  • Bayer AG
  • BeiGene, Ltd.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • C4 Therapeutics, Inc.
  • CRISPR Therapeutics AG
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GSK plc
  • Incyte Corporation
  • Iovance Biotherapeutics, Inc.
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson
  • Legend Biotech Corporation
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Seagen Inc.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 225.03 Billion
Forecasted Market Value ( USD ) by 2032 $ 347.87 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Cancer Biological Therapy - Global Strategic Business Report - Product Image

Cancer Biological Therapy - Global Strategic Business Report

  • Report
  • 211 Pages
  • Global
From
Combination Antibody Therapy Market - Global Forecast 2026-2032 - Product Image

Combination Antibody Therapy Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
CD Antigen Cancer Therapy Market - Global Forecast 2026-2032 - Product Image

CD Antigen Cancer Therapy Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Antineoplastic Agents - Global Strategic Business Report - Product Image

Antineoplastic Agents - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Cancer Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Cancer Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.